http://www.acc.org/Feed?clinicalTopicID=24942ad7-6be3-4248-afab-2113c3c5faf5 Clinical Topic Feed: Stable Ischemic Heart Disease en /Latest-in-Cardiology/Articles/2026/04/09/13/37/ai-enabled-clinician-09apr2026 In this episode, ACC Chief Innovation Officer Dr. Ami Bhatt speaks with Dr. Todd Villines about the transformative role of AI-enabled coronary CT angiogram (CCTA) and how it is expanding patient access to essential coronary artery disease (CAD) diagnostics. 1775748600000 Articles and Stories /Latest-in-Cardiology/Articles/2022/01/01/01/01/ACC-Featured-Jobs Ready to explore a new professional opportunity? Browse the list below of featured jobs and take the next step in your career! 1775037480000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sun-830am-orbita-cto-acc-2026 In patients with symptomatic single-vessel coronary chronic total occlusion (CTO), PCI for CTO improved angina beyond placebo, according to findings from the ORBITA-CTO trial presented at ACC.26 and simultaneously published in JACC. 1774791000000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/25/21/27/sat-930am-stemidtu-acc-2026 Compared with immediate PCI alone, the combination of mechanical left ventricular (LV) unloading using a transvalvular micro-axial flow pump (TV-mAFP) plus delayed PCI did not reduce infarct size in patients with anterior STEMI without cardiogenic shock, according to findings from the STEMI-DTU trial presented at ACC.26 and simultaneously published in JACC. 1774708320000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/03/19/17/12/Dobermann Two brief reports in JACC on the DOBERMANN-T and DOBERMANN-D trials found that among patients with acute myocardial infarction (AMI) at increased risk of cardiogenic shock (CS), early interleukin 6 (IL 6) receptor inhibition with tocilizumab safely reduced systemic inflammation but showed inconclusive effects on NT proBNP. In contrast, early dobutamine infusion did not lower NT proBNP levels but did reduce systolic blood pressure (SBP) without raising safety concerns. 1773942840000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/16/16/27/Pre-Hospital-Glycoprotein-IIb-IIIa-Inhibition-With-Zalunfiban-in-STEMI The CELEBRATE (CeleCor Blinded Randomized Trial in ST-Elevation Myocardial Infarction) trial was a phase 3, multicenter, double-blind, placebo-controlled study that evaluated the efficacy and safety of a single subcutaneous injection of zalunfiban (CeleCor Therapeutics), a novel glycoprotein IIb/IIIa inhibitor... 1773751800000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/09/15/44/Emerging-Trends-in-Multimodality-Cardiovascular-Imaging-at-AHA25 The American Heart Association (AHA) Scientific Sessions 2025 (AHA25) highlighted how quickly cardiovascular (CV) imaging is shifting toward integrated, biology-centered care. 1773077700000 Articles and Stories /Latest-in-Cardiology/Articles/2026/03/01/01/JACC-in-a-Flash Featured topics and Editors' Picks from all of ACC's JACC Journals. 1772370600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/02/25/15/49/ai-enabled-clinician-26feb2025 In this episode, ACC Chief Innovation Officer Dr. Ami Bhatt is joined by Dr. Geoffrey Rose to explore the impact of artificial intelligence (AI)-enabled plaque analysis and its integration into clinical workflows. 1772121120000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/02/25/19/29/NSTEMI-Algorithm Both the European Society of Cardiology 0/1-hour algorithm (ESC 0/1h-algorithm) and the high-sensitivity troponin in the evaluation of patients with acute coronary syndrome 0/2-hour or 0/3-hour pathway (High-STEACS 0/2h-0/3h-pathway) demonstrated "comparable and excellent performance" in diagnosing patients presenting with acute chest discomfort, according to a prospective, multicenter study published in JACC. 1772051220000 Articles and Stories